Ratings Sinocelltech Group Limited

Equities

688520

CNE100003ZL3

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-08 EDT			5-day change	1st Jan Change
50.68 ^CNY	+0.72%		+1.69%	-5.92%

04-25	Sinocelltech Group Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Sinocelltech Forecasts Return to Profit in Q1	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 80.44 times its estimated earnings per share for the ongoing year.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SINOCELLTECH GROUP LIMITED	-5.92%	3.1B	-
VERTEX PHARMACEUTICALS INCORPORATED	+2.81%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+10.29%	105B	B+
ARGENX SE	+1.57%	23.46B	B
BIONTECH SE	-12.43%	21.72B	B+
GENMAB A/S	-7.05%	18.64B	A-
WUXI APPTEC CO., LTD.	-37.64%	17.45B	A-
BEIGENE, LTD.	-6.57%	17.19B	B
NEUROCRINE BIOSCIENCES, INC.	+6.13%	13.99B	C+
SAREPTA THERAPEUTICS, INC.	+36.94%	12.53B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes